Patent ID: 7008637
Filing Date: 2006-03-07
Classification: A61K,A61P

Abstract:
1. A delivery system comprising: at least one compound selected from the group consisting of R-tolterodine, salts thereof, prodrugs thereof and metabolites thereof; and at least one device for transdermal administration of said at least one compound, said device selected from the group consisting of a reservoir, a matrix, a drug-in-adhesive, a multi-laminate, a polymer-system with no foils, an iontophoretic and combinations thereof, an electroporation, an electroosmosis, an electroincorporation a jet injection device, said device containing said at least one compound, and said device having an hourly flux rate of tolterodine of about 0.1 μg/h/cm at least one formulation for oral, sublingual, buccal, nasal, pulmonary, rectal and/or other transmucosal administration of said at least one compound, to a human being or an animal in order to achieve an effect against overactive bladder and/or symptoms associated with this condition.